Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2025

Description

+ Include:  videos + file sub vtt +  pdf, size:  GB

+ Target Audience: Neurologists, Neuro-Ophthalmologists, Neuroradiologists, Neuroimmunologists, Geriatricians, and Physical Medicine and Rehabilitation Specialists

+ Sample video: contact me for sample video

+ Information:

The ACTRIMS Forum 2025 (Americas Committee for Treatment and Research in Multiple Sclerosis) is the premier North American scientific conference dedicated to cutting-edge research, clinical advances, and therapeutic breakthroughs in multiple sclerosis (MS) and related neuroinflammatory disorders. Centered around the overarching theme of neurobiological connectivity, the 2025 Forum examines MS across the full spectrum: from visual pathway connections, advanced structural and functional brain network imaging, and regional CNS/systemic pathology, to the biological interplay between aging and disability accumulation. The program brings together global leaders to explore emerging concepts in remyelination and neuroprotection, machine learning in clinical practice, novel disease-modifying therapy (DMT) optimization, Bruton’s tyrosine kinase (BTK) inhibition for smoldering neuroinflammation, and modern management paradigms in neuromyelitis optica spectrum disorder (NMOSD).

Learning Objectives

Upon completion of this activity, participants should be able to:

• Evaluate structural, functional, and visual pathway connectivity to track disease progression, axonal loss, and visual deficits in multiple sclerosis and related disorders.

• Apply advanced multimodal neuroimaging techniques to assess brain network disruption, microstructural injury, and treatment response in MS.

• Analyze the pathophysiological intersection of chronological aging, cellular senescence, and progressive disability accumulation in MS.

• Integrate high-efficacy disease-modifying therapy (DMT) strategies, timing, and therapeutic sequencing to optimize long-term clinical and radiological outcomes.

• Describe the mechanisms of smoldering neuroinflammation and evaluate emerging targeted therapeutics, including Bruton’s tyrosine kinase (BTK) inhibitors.

• Formulate evidence-based diagnostic and therapeutic transition strategies for neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody-associated disease (MOGAD).

• Assess the utility of artificial intelligence, machine learning, and computational data models in predicting MS disease trajectories and personalizing clinical care.

Target Audience

This activity is intended for academic and clinical neurologists, MS subspecialists, neuro-ophthalmologists, neuroradiologists, basic and translational neuroscientists, immunology researchers, fellows, residents, physician assistants, nurse practitioners, specialized nurses, and other healthcare professionals dedicated to the care of patients with multiple sclerosis and related neuroinflammatory and demyelinating conditions.

Best for Neurologists, Neuro-Ophthalmologists, Neuroradiologists, Neuroimmunologists, Geriatricians, and Physical Medicine and Rehabilitation Specialists (Physiatrists).

Topics

• Welcome & Kenneth P. Johnson Memorial Lecture

• IMSVISUAL Symposium: Connections Along and Beyond the Visual Pathway

• NAIMS Symposium: Imaging Brain Connections Using Structural and Functional Methods

• LACTRIMS and European Charcot Foundation Joint Symposium: Global Connections

• National MS Society Barancik Award Presentation and Talk

• Cutting Edge Developments (CE1 & CE2)

• Late Breaking Research and Clinical Trials (LB1)

• Session 1: Emerging Concepts in MS

• Session 2: Connecting Aging to MS Pathology & Progression

• Session 3: Connecting to Diseases Beyond MS

• Session 4: Regional Connections in MS, Within & Beyond the CNS

• Session 5: Connecting Data to the Clinic Using Machine Learning

• Session 6: New Concepts in Repairing and Protecting Connections

• Industry Supported Satellite Symposium 1: BTK Inhibition as an MS Treatment Strategy Targeting Smoldering Neuroinflammation

• Industry Supported Satellite Symposium 2: Navigating and Pioneering High Efficacy DMT Strategies – Optimizing Patient Outcomes in Multiple Sclerosis

• Industry Supported Satellite Symposium 3: Time for a Reset: Using Modern Tools and Frameworks to Reengineer Multiple Sclerosis Management

• Industry Supported Satellite Symposium 4: A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden